The era of the integrase strand transfer inhibitors (INSTIs) for the treatment of human immunodeficiency virus (HIV) infection began with raltegravir in 2024. Since that time, several other INSTIs ha
by KK Scarsi 2024 Cited by 118Since 2024, five INSTIs have been introduced: raltegravir, elvitegravir, dolutegravir, bictegravir, and cabotegravir. The INSTIs have favorable pharmacokinetic
Drugs Calculators Charts Resources Multimedia Meetings Jobs. Part of INSTI and non-INSTI regimens, changes in BMI, and diabetes
INSTI-experienced patients with certain INSTI-associated resistance substitutions or clinically suspected INSTI resistance: 50 mg orally twice a day Comments:-Rilpivirine dose is 25 mg orally once a day for patients switching to this drug plus rilpivirine.
by SJ Smith 2024 Cited by 24Both DTG and BIC potently inhibit most INSTI-resistant IN mutants selected by the INSTIs raltegravir (RAL) and elvitegravir (EVG).
No resistance to the Cabotegravir (or other integrase inhibitor [INSTI] drugs) drugs – again to reduce the risk of developing drug resistance
Recommended ART regimens for treatment-naive patients with HIV infection are INSTI-based, and are as follows: drugs - darunavir
Considering the increasing interest in INSTIs for HIV-1 treatment, we focus our review on the retroviral integrase, development of INSTIs and their mode of action. We also discuss each of the INSTI drugs, including potential drug resistance and known side effects.
Weight gain and metabolic alterations have been reported with INSTI- and TAF-based antiretroviral regimens1–3. Cabotegravir (CAB), an INSTI, and
Comments